

#4

03CO

#16

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

|                   |   |                 |               |
|-------------------|---|-----------------|---------------|
| Applicant(s)      | Kerr-Conte et al.   | Examiner:       | Unassigned    |
| Serial No.:       | 09/960,632  | Group Art Unit: | Unassigned    |
| Confirmation No.: | 4273  | Docket:         | 855-21        |
| Filed:            | September 21, 2001  | Dated:          | April 8, 2002 |
| For:              | PROCESS FOR<br>OBTAINING<br>MAMMALIAN INSULIN<br>SECRETING CELLS IN<br>VITRO AND THEIR USES |                 |               |

US Patent and Trademark Office  
Box Sequence  
PO Box 2327  
Arlington, VA 22202

*I hereby certify this correspondence is being  
deposited with the United States Postal Service as  
first class mail, postpaid in an envelope, addressed  
to:*

*U.S. Patent and Trademark Office, Box Sequence,  
PO Box 2327, Arlington, VA 22202  
20231 on April 8, 2002*

Signature: *Michelle R. Spore*

**COMMUNICATION TO COMPLY WITH REQUIREMENTS  
FOR PATENT APPLICATION CONTAINING NUCLEOTIDE  
SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

Sir:

In response to a Notice to Comply with Requirements for Patent Applications Containing  
Nucleotide Sequence and/or Amino Acid Sequence Disclosure mailed February 8, 2002,  
Applicants enclose herewith the following:

1. A substitute diskette containing the Sequence Listing in computer-readable form;
2. A substitute paper copy of the Sequence Listing; and
3. A copy of the Notice.

Application No.: 09/960,632  
Filing Date: September 21, 2001  
Docket: 855-21  
Page 2

---

Applicants submit that the Sequence Listing conforms with the Notification to Comply.

Under 37 C.F.R. 1.821(f), the Applicants' attorney hereby states that the contents of the computer readable form and the paper copy are the same. Under 37 C.F.R. §1.821(g), the Applicants' attorney also states that the inclusion of this Sequence Listing does not include any new matter.

Accordingly, it is respectfully requested that the Sequence Listing be entered into the application.

If the Examiner has any questions relating to this Amendment or to this application in general, it is respectfully requested that the Examiner contact the Applicants' undersigned attorney at the telephone number provided below.

Respectfully submitted,



---

Lauren T. Emr  
Registration No. 46,139

HOFMANN & BARON, LLP  
6900 Jericho Turnpike  
Syosset, New York 11791  
(516) 822-3550  
LTE/nr




## UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov

| APPLICATION NUMBER | FILING/RECEIPT DATE | FIRST NAMED APPLICANT | ATTORNEY DOCKET NUMBER |
|--------------------|---------------------|-----------------------|------------------------|
| 09/960,632         | 09/21/2001          | Julie Kerr-Conte      | 855-21                 |

Irving N. Feit, Ph.D.  
HOFFMANN & BARON LLP  
6900 Jericho Turnpike  
Syosset, NY 11791



CONFIRMATION NO. 4273

FORMALITIES LETTER



\*OC000000007444536\*

Date Mailed: 02/08/2002

### NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d). Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or [patin3help@uspto.gov](mailto:patin3help@uspto.gov)

*A copy of this notice **MUST** be returned with the reply.*

Customer Service Center  
Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE